Indefinite Delivery Contract SPE2DU25D9260

The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) between the Defense Logistics Agency (DLA) and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,999,999 IDC was awarded on September 1, 2025 and is valid through December 31, 2036, providing the DLA with a mechanism to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide.

The IDC encompasses an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This contract position DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, enabling direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites. The original solicitation, a pre-solicitation notice for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract, indicates the DLA's intent to establish multiple regional primary supplier awards valued at a total of $30.3 billion to provide worldwide pharmaceutical support to various DoD customers.